OS rates
| . | HCT (n = 14) . | SOT (n = 12) . | Total (N = 26) . |
|---|---|---|---|
| Status, n (%) | |||
| Death | 5 (35.7) | 2 (16.7) | 7 (26.9)∗ |
| Censored | 9 (64.3) | 10 (83.3) | 19 (73.1) |
| OS estimate (KM) (mo) | |||
| Median (95% CI) | NE (1.5-NE) | NE (8.2-NE) | NE (8.2-NE) |
| OS rate (KM) (95% CI), % | |||
| 6 mos | 61.5 (30.8-81.8) | 91.7 (53.9-98.8) | 75.8 (53.8-88.3) |
| 12 mos | 61.5 (30.8-81.8) | 81.5 (43.5-95.1) | 70.0 (46.5-84.7) |
| 24 mos | 61.5 (30.8-81.8) | 81.5 (43.5-95.1) | 70.0 (46.5-84.7) |
| Follow-up time (mo) | |||
| Median (range) | 2.8 (1.0-25.3)† | 22.5 (2.6-26.2) | 8.2 (1.0-26.2) |
| . | HCT (n = 14) . | SOT (n = 12) . | Total (N = 26) . |
|---|---|---|---|
| Status, n (%) | |||
| Death | 5 (35.7) | 2 (16.7) | 7 (26.9)∗ |
| Censored | 9 (64.3) | 10 (83.3) | 19 (73.1) |
| OS estimate (KM) (mo) | |||
| Median (95% CI) | NE (1.5-NE) | NE (8.2-NE) | NE (8.2-NE) |
| OS rate (KM) (95% CI), % | |||
| 6 mos | 61.5 (30.8-81.8) | 91.7 (53.9-98.8) | 75.8 (53.8-88.3) |
| 12 mos | 61.5 (30.8-81.8) | 81.5 (43.5-95.1) | 70.0 (46.5-84.7) |
| 24 mos | 61.5 (30.8-81.8) | 81.5 (43.5-95.1) | 70.0 (46.5-84.7) |
| Follow-up time (mo) | |||
| Median (range) | 2.8 (1.0-25.3)† | 22.5 (2.6-26.2) | 8.2 (1.0-26.2) |
KM, Kaplan-Meier; NE, not evaluable.
None were treatment-related per investigator assessment.
Of 14 HCT recipients, 9 had OS follow-up of <4.5 months because of either death (n = 5) or study discontinuation (n = 4). Of the remaining 5 patients, 3 survived up to the 2-year study completion and 2 were censored between 8 and 13 months, with 1 exiting the study 5 months after treatment discontinuation because of start of subsequent therapy and 1 achieving maximal response. Maximum follow-up for the HCT cohort was 25.3 months, enabling the computation of OS rate estimates up to 24 months, including 95% CIs.